In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) plus gemcitabine (Gemzar) in children and young adults with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that this combination is safe and shows promising effectiveness in these...
Read MoreIn a nutshell This study is evaluating the safety and effectiveness of a new drug called lisocabtagene maraleucel compared to standard chemotherapy for relapsed (recurrent) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). The main outcome to be measured will be time to any disease-related complication. The...
Read More
In a nutshell This study looked at the effectiveness of adding inotuzumab ozogamicin (Besponsa) and blinatumomab (Blincyto) to low-intensity chemotherapy in the treatment of ALL. Researchers found that this combination of treatment was effective in these patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone marrow. This...
Read More
In a nutshell This study looked at the safety and effectiveness of blinatumomab (Blincyto) in the treatment of unresponsive acute lymphoblastic leukemia (ALL). Researchers found that blinatumomab was safe and effective in the treatment of these patients. Some background Acute lymphoblastic leukemia is a type of cancer of the bone marrow. This can lead...
Read More
In a nutshell This study investigated the effectiveness and safety of regorafenib (Stivarga) to treat patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC) that progressed after initial treatment. Researchers suggested that regorafenib is a safe option to treat these patients. Some background The standard treatment...
Read More
In a nutshell This article reviewed current treatment options for patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) diffuse large B-cell lymphoma (DLBCL). Some background DLBCL is one of the most common types of non-Hodgkin’s lymphoma. Typical first-line (primary) treatment involves chemoimmunotherapy....
Read More
In a nutshell This study evaluated the long-term survival and safety of brentuximab vedotin (Adcetris) treatment for patients with classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation (auto-SCT; patient's own healthy stem cells are retrieved and then returned into the body after cancer has been removed with chemotherapy...
Read More
In a nutshell This study investigated the effectiveness and safety of lenalidomide (Revlimid) plus everolimus (Afinitor) in pretreated patients with relapsed (recurrent) or refractory (does not respond to treatment) lymphoma. This study concluded that this combination was well-tolerated and showed promising effectiveness in these patients. Some...
Read More
In a nutshell This study investigated the effectiveness and safety of lenalidomide (Revlimid) plus everolimus (Afinitor) in pretreated patients with relapsed (recurrent) or refractory (does not respond to treatment) lymphoma. This study concluded that this combination was well-tolerated and showed promising effectiveness in these patients. Some...
Read More
In a nutshell This study compared the effectiveness of mogamulizumab (Poteligeo) versus vorinostat (Zolinza) in patients with previously treated cutaneous (skin) T-cell lymphoma (CTCL). This study concluded that mogamulizumab was well-tolerated and significantly more effective than vorinostat in these patients. Some background CTCL is a rare type of...
Read More
In a nutshell This study looked at the safety and effectiveness of using stem cells from the umbilical cord to reduce the return of disease in acute leukemia. Researchers found that stem cells from the umbilical cord were more effective than stem cells from other areas in the treatment of acute leukemia. Some background Refractory acute leukemia (rAL)...
Read More
In a nutshell This study aimed to investigate the use of dexamethasone, instead of prednisone, used with abiraterone acetate (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC). This study found that prednisone to dexamethasone switch can benefit some patients with mCRPC. Some background Androgen deprivation therapy...
Read More
